CurrentCignaPolicy N/A

Vitamin D Analog (Oral) Step Therapy Policy

Defines step therapy requirements for coverage of oral vitamin D analog medications for Cigna-administered health benefit plans; affects prescribers and payers determining prior authorization for listed products.

Policy Summary

PayerCigna

PolicyVitamin D Analog (Oral) Step Therapy Policy

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateSep 10, 2025

Key ActionRequire trial of one Step 1 product prior to approval of a Step 2 product; approvals provided for 1 year when criteria are met.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2Step levels

1 yrApproval duration

Rayaldee excludedAgent note

KDIGO 2017Referenced guideline

Coverage Criteria — Oral Vitamin D Analogs

Step Therapy Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Step therapy sequence: Patient has tried one Step 1 product prior to Step 2 producttrial of one Step 1 product

Step 1 products are generic calcitriol capsules or generic calcitriol oral solution

Alternate pathway: Patient has tried intravenous (IV) calcitriol injectiontrial of IV calcitriol

If met, approve a Step 2 product

The Kidney Disease: Improving Global Outcomes (KDIGO) guidance and individual product labeling should be considered when applying these step therapy rules. KDIGO 2017 advises against routine use of calcitriol and other vitamin D analogs in patients with CKD Stages 3a–5 not on dialysis, reserving use for severe or progressive secondary hyperparathyroidism, and suggesting calcimimetics, calcitriol, or vitamin D analogs (or combinations) for patients on dialysis who require PTH-lowering therapy. These guideline considerations may influence clinical decision-making and the medical necessity determination for a given patient.

Note that individual product indications also affect applicability: for example, Rayaldee (calcifediol extended‑release capsule) is not indicated for patients receiving dialysis, whereas most other oral vitamin D analogs are indicated for use in dialysis patients. Apply the step therapy requirements in the context of these product‑specific indications and KDIGO recommendations when determining coverage.

Provider Actions and Program Rules

Step Therapy

Step therapy requirement

This program requires that prescribers attempt Step 1 products before Step 2 products. If the Step Therapy rule is not met at the point of service, coverage will be determined using the step therapy criteria below and coverage may be denied or the claim reversed. Approvals granted when criteria are met are valid for 1 year.

Step 1 products: generic calcitriol capsules, generic calcitriol oral solution
Step 2 products: generic doxercalciferol capsules, generic paricalcitol capsules, Rayaldee capsules, Rocaltrol capsules (brand), Rocaltrol oral solution (brand), Zemplar capsules
Approvals: 1 year duration
Coverage determination: at point of service if step not met — may be denied or claim reversed

Documentation Required

Billing and documentation expectations

Providers must submit prior authorization or coverage requests in accordance with the member's benefit plan terms and supply appropriate diagnosis and procedure codes. Coverage is subject to medical necessity and the specific step therapy criteria.

Submit requests per benefit plan document and applicable laws/regulations
Use most appropriate coding as of the date of submission
Claims lacking covered diagnosis/procedure codes will be denied

Denial Risk

Step therapy enforcement

Coverage of a Step 2 product requires meeting one of the step criteria below; if the step therapy rule is not satisfied at the point of service, the Step 2 claim may be denied or reversed. Exceptions to the step therapy requirements are treated as not medically necessary unless they meet documented criteria.

If patient has tried one Step 1 product, approve Step 2 product
If patient has tried IV calcitriol injection, approve Step 2 product
Any other exception is considered not medically necessary

Background

Oral vitamin D analogs are used primarily to manage secondary hyperparathyroidism associated with chronic kidney disease (CKD). Most oral agents are indicated for patients not on dialysis and, with the exception of Rayaldee, are also indicated for patients receiving dialysis. Calcitriol formulations (capsules and oral solution) additionally have an indication for treating hypocalcemia in certain hypoparathyroidism diagnoses. KDIGO 2017 guidance no longer recommends routine use of calcitriol and analogs in CKD Stages 3a–5 (not on dialysis) and suggests reserving these agents for patients with severe or progressive hyperparathyroidism; for patients on dialysis who need PTH lowering, calcimimetics, calcitriol, or vitamin D analogs (or combinations) are reasonable options.

Definitions

Secondary hyperparathyroidism — definition

DefinitionA complication of chronic kidney disease (CKD) characterized by elevated parathyroid hormone levels; managed with vitamin D analogs and other agents.

Typical clinical contextOccurs in patients with CKD not on dialysis; most oral vitamin D analogs are indicated for this use.

Dialysis noteAll oral agents except Rayaldee are also indicated for secondary hyperparathyroidism in patients receiving dialysis.

Therapeutic considerationsKDIGO 2017 recommends against routine use of calcitriol and analogs in CKD stages 3a–5 not on dialysis; reserve for severe or progressive hyperparathyroidism.

Related indicationsCalcitriol capsules and oral solution additionally indicated for hypocalcemia in certain hypoparathyroidism diagnoses.

Initial Therapy Criteria / Step Assignments

Step assignments for initial therapy

Step 1: generic calcitriol capsules OR generic calcitriol oral solution must be tried first

Step 1 products listed in policy

Step 2: After Step 1 trial, eligible products include generic doxercalciferol capsules, generic paricalcitol capsules, Rayaldee capsules, Rocaltrol (brand) capsules and oral solution, Zemplar capsules

Step 2 products listed in policy

Step Therapy Operational Details

Requirement	Details	Coverage
Step therapy trial of a Step 1 product	Patient must have tried one Step 1 product (Step 1 products: generic calcitriol capsules or generic calcitriol oral solution).	Covered when requirement met
Prior IV calcitriol trial	A trial of intravenous (IV) calcitriol injection satisfies the Step 1 requirement and may be used in lieu of an oral Step 1 trial.	Covered when requirement met
Approval duration	Approvals for Step 2 products are provided for 1 year when criteria are met.	Neutral